ew diagnostic tests in autonomic failure to improve diagnosis for PAF and MSA patients.

Recruiting

Conditions: Autonomic failure
dysfunction of the autonomic nerve system
10042261
10034606

Registration Number: NL-OMON43607

Lead Sponsor: eids Universitair Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 33

Inclusion Criteria

All participants: older than 18 years and the ability to provide informed consent.
Patients with PAF are defined according to the consensus of the American Autonomic Society and the American Acedemy of Neurology (AAN):
- Presence of NOH AND
- Evidence of more widespread autonomic failure AND
- No other neurological features
Patients with MSA are defined according to the second consensus criteria of the AAN.
Healty controls: no signs of autonomic failure or other relevant neurological or other disorders.

Exclusion Criteria

For all participants: younger than 18 years or not able to provide informed consent.
Furthermore, a potential subject who meets any of the following criteria will be excluded from participation in this study:
- Diabetes Mellitus
- Inability to sustain the investigations due to the nature of their disease
- Ophtalmological morbidity: AMD, macular dystrophies, glaucoma, herpes keratitis, history of cornea surgery like refractive surgery

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- CCM : Difference in nerve fiber density in the cornea between patients with<br /><br>PAF, patients with MSA and controls. A difference of 14.2 fibers / mm2 between<br /><br>groups is regarded as a minimal clinically relevant difference .<br /><br>- OCT: Difference in the RNFL (Retinal Nerve Fiber Layer) thickness between<br /><br>patients with PAF, patients with MSA and controls.<br /><br>- WISW : Difference in the degree of wrinkling of the skin in the fingertips<br /><br>between patients with PAF, patients with MSA and controls. A difference of 1 '<br /><br>grade ' between goups is considered a minimal clinically relevant difference .<br /><br>- Sudoscan: Difference in electrochemical skin conductance in microsiemens (µS)<br /><br>between patients with PAF, patients with MSA and controls. A difference in skin<br /><br>conductance of 10 µS between groups is considered the minimal clinically<br /><br>relevant difference.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>ROX: difference in the arterial and venous oxygenation during a fall in blood<br /><br>pressure among patients with PAF, patients with MSA and controls.</p><br>